Philip A Watson
Overview
Explore the profile of Philip A Watson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
3927
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zaidi S, Park J, Chan J, Roudier M, Zhao J, Gopalan A, et al.
Proc Natl Acad Sci U S A
. 2024 Jul;
121(28):e2322203121.
PMID: 38968122
Targeting cell surface molecules using radioligand and antibody-based therapies has yielded considerable success across cancers. However, it remains unclear how the expression of putative lineage markers, particularly cell surface molecules,...
2.
Zaidi S, Park J, Chan J, Roudier M, Zhao J, Gopalan A, et al.
bioRxiv
. 2024 Apr;
PMID: 38645034
Targeting cell surface molecules using radioligand and antibody-based therapies has yielded considerable success across cancers. However, it remains unclear how the expression of putative lineage markers, particularly cell surface molecules,...
3.
Targeting prostate tumor low-molecular weight tyrosine phosphatase for oxidation-sensitizing therapy
Stanford S, Nguyen T, Chang J, Zhao Z, Hackman G, Santelli E, et al.
Sci Adv
. 2024 Jan;
10(5):eadg7887.
PMID: 38295166
Protein tyrosine phosphatases (PTPs) play major roles in cancer and are emerging as therapeutic targets. Recent reports suggest low-molecular weight PTP (LMPTP)-encoded by the gene-is overexpressed in prostate tumors. We...
4.
Wasmuth E, Vanden Broeck A, LaClair J, Hoover E, Lawrence K, Paknejad N, et al.
Mol Cell
. 2022 Apr;
82(11):2021-2031.e5.
PMID: 35447082
The androgen receptor (AR) is a nuclear receptor that governs gene expression programs required for prostate development and male phenotype maintenance. Advanced prostate cancers display AR hyperactivation and transcriptome expansion,...
5.
Adams E, Karthaus W, Hoover E, Liu D, Gruet A, Zhang Z, et al.
Nature
. 2020 Sep;
585(7826):E20.
PMID: 32895534
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
6.
Zhang Z, Karthaus W, Lee Y, Gao V, Wu C, Russo J, et al.
Cancer Cell
. 2020 Jul;
38(2):279-296.e9.
PMID: 32679108
Despite the development of second-generation antiandrogens, acquired resistance to hormone therapy remains a major challenge in treating advanced prostate cancer. We find that cancer-associated fibroblasts (CAFs) can promote antiandrogen resistance...
7.
Leibold J, Ruscetti M, Cao Z, Ho Y, Baslan T, Zou M, et al.
Cancer Discov
. 2020 May;
10(7):1038-1057.
PMID: 32376773
To study genetic factors influencing the progression and therapeutic responses of advanced prostate cancer, we developed a fast and flexible system that introduces genetic alterations relevant to human disease directly...
8.
Kim K, Hu W, Audenet F, Almassi N, Hanrahan A, Murray K, et al.
Nat Commun
. 2020 Apr;
11(1):1975.
PMID: 32332851
Treatment paradigms for patients with upper tract urothelial carcinoma (UTUC) are typically extrapolated from studies of bladder cancer despite their distinct clinical and molecular characteristics. The advancement of UTUC research...
9.
Adams E, Karthaus W, Hoover E, Liu D, Gruet A, Zhang Z, et al.
Nature
. 2019 Jun;
571(7765):408-412.
PMID: 31243370
Mutations in the transcription factor FOXA1 define a unique subset of prostate cancers but the functional consequences of these mutations and whether they confer gain or loss of function is...
10.
Lee E, Wongvipat J, Choi D, Wang P, Lee Y, Zheng D, et al.
Elife
. 2019 Jan;
8.
PMID: 30644358
Genomic amplification of the androgen receptor () is an established mechanism of antiandrogen resistance in prostate cancer. Here, we show that the magnitude of signaling output, independent of genomic alteration...